Boteng is the top three pharmaceutical R&D and production outsourcing organization (CDMO) in China, which is mainly committed to providing customized R&D and customized production services for pharmaceutical companies and new drug R&D organizations around the world from early clinical research to drug listing.
It is the leading pharmaceutical R&D and production outsourcing organization (CDMO) in China. Headquartered in Chongqing, China, the company has subsidiaries in Chengdu, Shanghai, Yichun, Jiangxi, China, Hongkong, Belgium, Switzerland and the United States.
In mid-May 2020, the Shanghai R&D Center project of Chongqing Boteng Pharmaceutical Co., Ltd., a subsidiary of Boteng Co., Ltd., officially started construction. This is the third pharmaceutical R&D laboratory after Chongqing R&D laboratory and New Jersey laboratory.
The R&D Center is expected to be completed and put into use in June 2020. By then, 19 pharmaceutical laboratories and 7 analytical laboratories will be built to provide customers with one-stop service for bringing new drugs to market faster and better.